Protagonist Therapeutics Inc (PTGX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $8.55B
Last updated: Nov 17, 2026 at 11:06 AM ET
Protagonist Therapeutics Inc (PTGX) Competitors
The companies most similar to Protagonist Therapeutics are TG Therapeutics (TGTX), PTC Therapeutics (PTCT) and Apogee Therapeutics, Inc. Common Stock (APGE). Protagonist Therapeutics trades at 27.7x earnings, against a median of 66.5x for the 3 of these companies with a P/E. By market cap, Protagonist Therapeutics ranks 9th of the 13 companies on this page; BridgeBio Pharma (BBIO) is the largest at $15.25B.
Peer Comparison
PTGX's revenue growth of 5724.0% is above the peer median of 43.2%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Protagonist Therapeutics (PTGX) | $8.55B | 27.7x | 15.8x | 62.0% | N/A | 5724.0% | 0.00% |
| TG Therapeutics Inc (TGTX) | $9.75B | 87.2x | 11.1x | 11.8% | 11.0% | 60.7% | 0.00% |
| PTC Therapeutics Inc (PTCT) | $5.30B | N/A | 5.2x | -9.2% | 18.1% | 69.6% | 0.00% |
| Apogee Therapeutics, Inc. Common Stock (APGE) | $10.22B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Praxis Precision Medicines Inc (PRAX) | $9.17B | N/A | N/A | 0.0% | N/A | 1349.0% | 0.00% |
| Summit Therapeutics PLC (SMMT) | $11.32B | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Spyre Therapeutics Inc. (SYRE) | $9.88B | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Dianthus Therapeutics Inc. (DNTH) | $5.17B | N/A | N/A | 0.0% | N/A | 205.6% | 0.00% |
| Krystal Biotech Inc (KRYS) | $9.05B | 40.4x | 18.8x | 47.9% | N/A | 30.2% | 0.00% |
| Ligand Pharmaceuticals Incorporated (LGND) | $6.18B | 66.5x | 23.7x | 20.3% | 0.1% | -31.8% | 0.00% |
| Travere Therapeutics Inc (TVTX) | $4.86B | N/A | 7.2x | -18.7% | -23.1% | 36.2% | 0.00% |
| Madrigal Pharmaceuticals Inc (MDGL) | $9.93B | N/A | 8.7x | -10.9% | -12.7% | 50.1% | 0.00% |
| BridgeBio Pharma Inc (BBIO) | $15.25B | N/A | 16.0x | -59.8% | -33.0% | 192.6% | 0.00% |
| Peer median | $9.46B | 66.5x | 11.1x | 0.0% | -6.3% | 43.2% | 0.00% |
Similar Companies
These are the 12 companies most similar to Protagonist Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| TG Therapeutics Inc (TGTX) | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development... | TGTX competitors |
| PTC Therapeutics Inc (PTCT) | PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. | PTCT competitors |
| Apogee Therapeutics, Inc. Common Stock (APGE) | Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)... | |
| Praxis Precision Medicines Inc (PRAX) | Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal... | PRAX competitors |
| Summit Therapeutics PLC (SMMT) | Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America... | SMMT competitors |
| Spyre Therapeutics Inc. (SYRE) | Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by... | SYRE competitors |
| Dianthus Therapeutics Inc. (DNTH) | Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops... | DNTH competitors |
| Krystal Biotech Inc (KRYS) | Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United... | KRYS competitors |
| Ligand Pharmaceuticals Incorporated (LGND) | Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover... | LGND competitors |
| Travere Therapeutics Inc (TVTX) | Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification... | TVTX competitors |
| Madrigal Pharmaceuticals Inc (MDGL) | Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates... | MDGL competitors |
| BridgeBio Pharma Inc (BBIO) | BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. | BBIO competitors |
Frequently Asked Questions About PTGX
Who are Protagonist Therapeutics' main competitors?
The companies most similar to Protagonist Therapeutics include TG Therapeutics (TGTX), PTC Therapeutics (PTCT), Apogee Therapeutics, Inc. Common Stock (APGE), Praxis Precision Medicines (PRAX) and Summit Therapeutics (SMMT), listed from the closest match.
Who is Protagonist Therapeutics' biggest competitor?
BridgeBio Pharma (BBIO) is the largest of the similar companies at $15.25B; TG Therapeutics (TGTX) is the closest match by business profile, size, sector and industry.
How does PTGX stock compare with its competitors?
PTGX's P/E is 27.7x against a peer median of 66.5x; its P/S is 15.8x against a peer median of 11.1x; its net margin is 62.0% against a peer median of 0.0%.
Which of Protagonist Therapeutics' competitors pays a higher dividend?
Protagonist Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Protagonist Therapeutics bigger than its competitors?
No. Protagonist Therapeutics is 9th by market cap among the 13 companies on this page; the largest is BridgeBio Pharma (BBIO) at $15.25B.
PTGX pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors